Skip to Main Content

Select Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source.


The Vera and Joseph Dresner Foundation MDS Research Fund
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).

The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards

Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Learn More>>

Launching soon: ASCI Emerging-Generation Awards

These awards recognize post-MD, pre-career physician-scientists who are meaningfully engaged in immersive research, giving them access to the Joint Meeting and longitudinal programming similar to the YPSA program. Entry into the ASCI network at this stage is intended to provide peer support and inspiration to stay the course into a physician-scientist faculty appointment.

Look for E-Gen Awards nominations to open in late October. Contact for more information.

Joint Developmental Research Program- Cancer Disparities Yale SPORE in Lung Cancer & Yale Head and Neck SPORE

Provide support of up to $50,000 for a translational pilot project focused on disparities-related cancer research in the field of Head and Neck and/or Lung cancer. Despite major progress in reducing cancer deaths and cancer incidence in the United States of America, health disparities exist across the country. Research in cancer disparities studies the differences in the incidence, prevalence, mortality, and burden of cancer and related adverse health conditions that exist among specific population groups in the U.S. These include American Indians / Alaskan Natives, Asian Americans, Black/African Americans, Hispanics/Latinos, Native Hawaiians and other Pacific Islanders, sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

Award Amounts: Up to $50,000 for one year commencing August 1, 2022.

Purpose: To provide seed money to investigators to support studies with a strong translational or clinical component that have the potential to evolve into, or be incorporated into, a full Yale SPORE project in either the Yale SPORE in Lung Cancer (YSILC) or Yale Head and Neck SPORE (YHN-SPORE). Projects with multi-disciplinary collaborations and community-based participatory research studies are encouraged.

Eligibility: Open to investigators who hold a faculty appointment at an academic institution who fall into one of the following categories:

1. Established investigators in lung or head and neck cancer who wish to address a translational question - not funded by current or pending grants/funds - related to cancer health disparities.

2. Junior investigators holding a faculty appointment proposing innovative research in the arena of cancer health disparities that require preliminary data to apply for an R01 or equivalent research support.

3. Independent investigators with a previous and/or current R01 or equivalent funding whose research to date has not been specifically directed at lung or head and neck cancer, or even at cancer more generally, but who are interested in exploring the applicability of their particular expertise to these cancer types in a translational cancer health disparities related project.

Women and minority investigators are strongly encouraged to apply.

Full applications are due: July 1, 2022

LOIs and full applications should be submitted online at:

2022 AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants
  • Victoria’s Secret Global Fund for Women’s Cancers 2022 Career Development Award, in partnership with Pelotonia & AACR - Application Deadline: June 28, 2022
  • AACR-Day One Biopharmaceuticals Pediatric Cancer Research Fellowship - Application Deadline: July 6, 2022

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)

This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Application Deadline: July 5, 2022

Learn more about Cancer Tissue Collaborative>>

Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21)

This FOA solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics.

Application Deadline: July 5, 2022

Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01, R21)

The purpose of this FOA is to solicit R01 and R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.
Application Deadline: June 5, 2022

Cancer Control Research in Persistent Poverty Areas (U54)

Through this FOA, the NCI invites applications for Cancer Control Research in Persistent Poverty Areas (Persistent Poverty Initiative). The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas.

Application Deadline: July 6, 2022

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)

The purpose of this FOA is to invite applications for TCORS to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the Research Objectives related to the regulatory authority of the FDA Center for Tobacco Products.

Application Deadline: July 14, 2022

Yale SPORE in Skin Cancer DRP and CEP Awards

Beginning September 1, 2022 these awards fund projects in amounts up to $50,000 for one year with the possibility of competing renewal for a second year of funding. DRP and CEP projects must have promising translational research potential with application to human skin cancer. It is expected that they can evolve into projects with a clear translational component that are suitable for funding either within the Yale SPORE in Skin Cancer or as R01 or equivalent grants.

Application Deadline: July 27, 2022

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44)

This FOA solicits SBIR applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.

Application Deadline: August 6, 2022

Gabrielle's Angel Foundation

The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment. Of interest are innovative clinical and basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies. Focus is on projects for cancer prevention, detection and treatment that are most likely to be translated into clinical trials within a 3-5 year period.

Internal Submission Deadline: August 8, 2022

DoD Breast Cancer Research Program Awards

These awards provide funding to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members, Veterans, and the general public.

  • Breakthrough Award Levels 1 and 2- LOI Due: September 22, 2022
  • Breakthrough Award Level 3- Pre-application Due: August 3, 2022
  • Breakthrough Award Level 4- Pre-application Due: August 3, 2022
  • Era of Hope Scholar Award- LOI Due: September 22, 2022
  • Innovator Award- LOI Due: August 3, 2022

Learn more about the DoD BCRP>>

DoD Ovarian Cancer Research Program Clinical Trial Award

This award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.

Application Deadline: August 5, 2022

Learn more about the DoD OCRP award>>

DoD Rare Cancers Research Program Awards

There are a significant number of incidences of rare cancers in the U.S. military population. Over 60 forms of cancer disproportionately impact those who have served in the military, and 67% of them are rare cancers. These awards support research on the prevention, detection, diagnosis, and treatment of Service Members, Veterans, their families, and the American public.

  • Concept Award- Application Deadline: August 29, 2022
  • Idea Development Award- Application Deadline: September 30, 2022
  • Resource and Community Development Award- Application Deadline: September 30, 2022

Learn more about the DoD RCRP>>

DoD Kidney Cancer Research Program (KCRP)

These awards support research of exceptional scientific merit in the area of kidney cancer.

  • Academy of Kidney Cancer Investigators Early-Career Scholar Award- LOI Due: September 29, 2022
  • Nurse-Initiated Research Award- LOI Due: September 29, 2022
  • Clinical Trial Award- LOI Due: September 29, 2022

Learn more about the KCRP Awards>>